Impedimed Ltd (ASX: IPD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Impedimed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$32.62 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.04 billion
Earnings per share
-0.012
Dividend per share
N/A
Year To Date Return
-52.94%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Impedimed Ltd (ASX: IPD)
Latest News
⏸️ Investing
Why these 4 ASX shares have started the week deep in the red
⏸️ Investing
Why these 4 ASX shares surged higher today
⏸️ Investing
Why these 4 ASX shares have bolted higher today
⏸️ Investing
5 explosive growth shares I will be watching in 2017
⏸️ Investing
4 small-cap shares I think could be set to soar in 2017
⏸️ Investing
3 game-changing companies to buy today
⏸️ Investing
Broker tips 9 small cap stars to buy in October
⏸️ Investing
Why the shares of biotech star Impedimed Limited are rocketing today
⏸️ Investing
3 explosive healthcare shares to give your portfolio a boost
⏸️ Investing
Beat the market with these 3 growing healthcare shares
⏸️ Investing
Here's why these 4 ASX shares are storming higher today
⏸️ Investing
Here's why the shares of biotech Impedimed Limited are soaring today
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Impedimed Ltd
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software SubscriptionServices.
IPD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,541,524 | $0.02 | $0.02 | $0.02 |
| 17 Mar 2026 | $0.02 | $0.00 | 0.00% | 256,414 | $0.02 | $0.02 | $0.02 |
| 16 Mar 2026 | $0.02 | $0.00 | 0.00% | 243,445 | $0.02 | $0.02 | $0.02 |
| 13 Mar 2026 | $0.02 | $0.00 | 0.00% | 6,443,102 | $0.02 | $0.02 | $0.02 |
| 12 Mar 2026 | $0.02 | $0.00 | 0.00% | 2,515,335 | $0.02 | $0.02 | $0.02 |
| 11 Mar 2026 | $0.02 | $0.00 | 0.00% | 299,219 | $0.02 | $0.02 | $0.02 |
| 10 Mar 2026 | $0.02 | $0.00 | 0.00% | 221,368 | $0.02 | $0.02 | $0.02 |
| 09 Mar 2026 | $0.02 | $0.00 | 0.00% | 3,107,189 | $0.02 | $0.02 | $0.02 |
| 06 Mar 2026 | $0.02 | $0.00 | 0.00% | 4,452,882 | $0.02 | $0.02 | $0.02 |
| 05 Mar 2026 | $0.02 | $0.00 | 0.00% | 474,924 | $0.02 | $0.02 | $0.02 |
| 04 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,749,956 | $0.02 | $0.02 | $0.02 |
| 03 Mar 2026 | $0.02 | $0.00 | 0.00% | 8,805,274 | $0.02 | $0.02 | $0.02 |
| 02 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,035,419 | $0.02 | $0.02 | $0.02 |
| 27 Feb 2026 | $0.02 | $0.00 | 0.00% | 13,062,200 | $0.02 | $0.02 | $0.02 |
| 26 Feb 2026 | $0.02 | $0.00 | 0.00% | 2,916,199 | $0.02 | $0.02 | $0.02 |
| 25 Feb 2026 | $0.02 | $0.00 | 0.00% | 19,955,821 | $0.02 | $0.02 | $0.02 |
| 24 Feb 2026 | $0.02 | $0.00 | 0.00% | 4,338,653 | $0.02 | $0.02 | $0.02 |
| 23 Feb 2026 | $0.02 | $0.00 | 0.00% | 11,580,953 | $0.02 | $0.02 | $0.02 |
| 20 Feb 2026 | $0.02 | $0.00 | 0.00% | 3,068,745 | $0.02 | $0.02 | $0.02 |
| 19 Feb 2026 | $0.02 | $0.00 | 0.00% | 455,064 | $0.02 | $0.02 | $0.02 |
| 18 Feb 2026 | $0.02 | $0.00 | 0.00% | 1,321,435 | $0.02 | $0.02 | $0.02 |
| 17 Feb 2026 | $0.02 | $0.00 | 0.00% | 4,323,951 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Feb 2026 | Christine Emmanuel-Donnelly | Buy | 1,500,000 | $29,359 |
On-market trade.
|
| 14 Jan 2026 | Christine Emmanuel-Donnelly | Issued | 146,408 | $5,197 |
Director remuneration.
|
| 14 Jan 2026 | Janelle Delaney | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 14 Jan 2026 | Andrew Grant | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 14 Jan 2026 | Fiona Bones | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Fiona Bones | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Andrew Grant | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Christine Emmanuel-Donnelly | Issued | 143,182 | $5,197 |
Director remuneration.
|
| 03 Nov 2025 | Janelle Delaney | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 31 Jul 2025 | Fiona Bones | Issued | 268,169 | $8,393 |
Director remuneration.
|
| 31 Jul 2025 | Janelle Delaney | Issued | 268,169 | $8,393 |
Director remuneration.
|
| 31 Jul 2025 | Christine Emmanuel-Donnelly | Issued | 474,084 | $14,838 |
Director remuneration.
|
| 31 Jul 2025 | Andrew Grant | Issued | 268,169 | $8,393 |
Director remuneration.
|
| 26 May 2025 | Christine Emmanuel-Donnelly | Buy | 306,446 | $9,519 |
On-market trade.
|
| 22 Apr 2025 | Andrew Grant | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 22 Apr 2025 | Christine Emmanuel-Donnelly | Issued | 349,412 | $14,850 |
Director remuneration.
|
| 22 Apr 2025 | Janelle Delaney | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 22 Apr 2025 | Fiona Bones | Issued | 197,647 | $8,399 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Parmjot Bains | Managing DirectorChief Executive Officer | Jan 2024 |
Dr Bains is a medical doctor with more than 30 years of healthcare experience including Pfizer and McKinsey across the United States, Asia, Middle East and Australia and also has 6 years Board/governance experience.
|
| Mr Andrew John Grant | Non-Executive Director | Sep 2023 |
Mr Grant has spent more than 20 years in gaining understanding and experience working with key US customers and across global healthcare markets. He has Strategic planning experience and delivery in healthcare working with healthcare organisations globally, including McKinsey and ResMed. He is also a member of Risk Committee.
|
| Mr McGregor Grant | Executive DirectorChief Financial Officer | Feb 2024 |
Mr Grant brings commercial and financial experience in growing global medical device businesses, most recently Nanosonics Limited. He has Board administration, governance and investor relations experience.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive DirectorNon-Executive Chairman | Sep 2023 |
Ms Emmanuel-Donnelly brings 30 years in IP experience through commercialisation and strategic in-house intellectual property roles. She has more than 5 years in Board and healthcare governance experience. She is a member of the Risk Committee
|
| Ms Janelle Delaney | Non-Executive Director | Sep 2023 |
Ms Delaney has more than 30 years of project management and execution at IBM, with responsibility for the quality of delivery across Asia Pacific's portfolio of several thousand projects. She is a member of Risk Committee.
|
| Ms Fiona Bones | Non-Executive Director | Jun 2024 |
Ms Bones brings more than 30 years of experience in the finance, corporate governance and systems transformation. She has global governance experience gained as Vice President of Finance, International Controller of Google. She is Chair of the Risk Committee.
|
| Mr Erik Anderson | Non-Executive Director | Feb 2026 |
Mr Anderson is a US Med Tech executive who spent over ten years at Hologic, Inc. (NASDAQ: HOLX). During his tenure at Hologic he held multiple President level roles, recently serving as Division President of the Breast & Skeletal Health Division. Erik also served as Division President of Cynosure, Hologic medical aesthetics business. Erik brings more than 16 years of experience in US hospital sales, health system account management, and the commercialisation of clinical technologies.
|
| Ms Leanne Ralph | Company Secretary | Jan 2015 |
-
|
| McGregor Grant | Chief Financial & Operating Officer/Executive Director |
-
|
|
| Steven Chen | Chief Medical Officer |
-
|
|
| Scott Savage | Chief Product Officer |
-
|
|
| Katie Newsome | Clinical Program Director |
-
|
|
| Leanne Ralph | Company Secretary |
-
|
|
| Ashley Munoz | Director Human Resources |
-
|
|
| Julie Kuhlken | Senior Director Marketing |
-
|
|
| Dennis Schlaht | SVP R&D and Technology |
-
|
|
| Scott Long | SVP Sales Key Accounts and Renewals |
-
|
|
| Mike Bassett | VP Business Development and Investor Relations |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 261,631,361 | 12.89% |
| J P Morgan Nominees Australia Pty Limited | 138,619,651 | 6.83% |
| Citicorp Nominees Pty Limited | 118,098,388 | 5.82% |
| HSBC Custody Nominees (Australia) Limited i | 56,309,393 | 2.77% |
| Bnp Paribas Nominees Pty Ltd | 56,121,481 | 2.76% |
| Bnp Paribas Noms Pty Ltd | 32,741,215 | 1.61% |
| Moore Family Nominee Pty Ltd | 30,000,000 | 1.48% |
| Mr Stephen Edward Mahnken | 28,900,000 | 1.42% |
| Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 27,300,000 | 1.34% |
| Mr Hamish Alexander Jones | 26,410,134 | 1.30% |
| Mba Investments Pty Ltd | 22,490,990 | 1.11% |
| Bsd Pty Ltd | 19,000,000 | 0.94% |
| Bilgola Nominees Pty Limited | 16,978,161 | 0.84% |
| Pakasoluto Pty Limited | 16,011,422 | 0.79% |
| Acadia Park Pty Ltd | 14,374,048 | 0.71% |
| Mr Philip Joseph Bare | 13,641,648 | 0.67% |
| Mid Dig Investments Pty Ltd | 12,411,897 | 0.61% |
| Hme Soo Holdings Pty Ltd | 12,320,921 | 0.61% |
| Mr Gregory Wayne Brown & Mrs Stefanie Brown | 10,927,869 | 0.54% |
| Sunlora Pty Ltd | 10,050,010 | 0.50% |